Recent developments include initiation of Phase IIb clinical trial for SCI-110 in Tourette Syndrome, acquisition of CliniQuantum by NeuroThera, and a C$5.4 million private placement financing by NeuroThera with SciSparc's stake valued at approximately C$30 million.

• SciSparc's subsidiary NeuroThera Labs initiated a Phase IIb clinical trial of SCI-110 for Tourette Syndrome in July 2026 [N3].
• NeuroThera Labs completed the acquisition of CliniQuantum in June 2026, with positive market reaction [N4].
• NeuroThera Labs completed a C$5.4 million private placement financing in August 2026, with SciSparc's stake valued at approximately C$30 million [S2].
• SciSparc signed a definitive agreement to acquire a treasury of patents for the endoscope market in January 2026 [N8].
• The company has been featured in biotech gainers lists in mid-2026, indicating market interest [N1][N5].

SciSparc's clinical-stage cannabinoid drug candidates, SCI-110 and SCI-210, have demonstrated safety and some efficacy signals in Phase IIa trials for neurological disorders with significant unmet medical needs. Regulatory approvals for Phase IIb trials in multiple countries and ongoing patient enrollment indicate progress in clinical development. The company's acquisition of patent portfolios and financing activities support its pipeline expansion and operational funding. If clinical trials continue to show positive results, SciSparc could advance its drug candidates toward potential regulatory approval pathways. The nutraceutical business provides some revenue diversification.

SciSparc faces significant challenges including limited current revenue primarily from its nutraceutical segment, ongoing operating losses, and an accumulated deficit. The company has limited liquidity with a current ratio below 1 as of mid-2025, indicating potential short-term financial constraints. Clinical development risks include the possibility that ongoing trials may not demonstrate sufficient efficacy or safety to support regulatory approval. The pharmaceutical market for cannabinoid therapies is competitive with larger companies possessing greater resources. Regulatory hurdles, pricing pressures, and reimbursement uncertainties may impact commercial viability. The company’s reliance on external financing and partnerships adds execution risk.

SciSparc's moat is based on its proprietary cannabinoid pharmaceutical formulations combining THC or CBD with its proprietary CannAmide™ (PEA) technology, which aims to induce a unique 'sparing effect' for treating central nervous system disorders. The company has advanced clinical-stage programs with regulatory approvals for Phase IIb trials in multiple jurisdictions, supported by positive Phase IIa data. Its patent portfolio expansion, including acquisitions of patents for endoscopic technologies, adds to its intellectual property assets. However, the company operates in a competitive pharmaceutical landscape with larger players developing cannabinoid therapies, and faces regulatory and reimbursement challenges that may limit market exclusivity and pricing power.

• Clinical Development Risk: SCI-110 and SCI-210 are in clinical trials with inherent risks that results may not support regulatory approval or commercial viability.
• Financial and Liquidity Risk: Operating losses and a current ratio of 0.55 as of June 30, 2025, indicate limited liquidity and ongoing need for financing.
• Regulatory Risk: Obtaining FDA orphan drug designation and regulatory approvals involves uncertainty and may require additional studies.
• Competitive Risk: The cannabinoid pharmaceutical market is competitive with larger companies having greater resources and established products.
• Market and Pricing Risk: Pricing and reimbursement challenges in the US and foreign markets may limit revenue potential and profitability.

• SciSparc Ltd. is an Israeli company incorporated in 2004, with principal offices in Tel Aviv [S1].
• The company operates primarily through its majority-owned subsidiary NeuroThera, focusing on clinical-stage pharmaceutical development based on cannabinoid pharmaceuticals [S1].
• Key drug candidates include SCI-110 (THC and CannAmide™ formulation) targeting Tourette Syndrome (TS) and Alzheimer's disease with agitation, and SCI-210 (CBD and CannAmide™) targeting Autism Spectrum Disorder (ASD) and Status Epilepticus (SE) [S1].
• SCI-110 has completed Phase IIa clinical trials for TS and Alzheimer's disease with agitation, showing safety and some efficacy signals [S1].
• Phase IIb clinical trials for SCI-110 in TS have been approved by regulatory authorities in Germany, Israel, and the US, with trials initiated in 2023 and enrollment ongoing [S1][N3].
• SCI-210 Phase IIa/IIb clinical trials for ASD have regulatory approvals and are underway with patient enrollment [S1].
• The company has outlicensed its SCI-160 program to Polyrizon and is no longer developing that product [S1].
• SciSparc also operates a nutraceutical business (SciSparc Nutraceuticals) selling hemp seed oil-based products under the Wellution™ brand on Amazon Marketplace [S1].
• The company has engaged in acquisitions, including NeuroThera's acquisition of CliniQuantum, and has signed agreements to acquire patent portfolios for endoscopic technologies [N4][N8].
• Recent financing includes a C$5.4 million private placement by NeuroThera, with SciSparc holding a stake valued at approximately C$30 million [S2].
• Financial snapshot as of June 30, 2025: cash and equivalents of $1.545 million, current assets of $2.749 million, current liabilities of $5.038 million, resulting in a current ratio of 0.55 and cash ratio of 0.31 [sec_financial_snapshot].
• Revenue for the year ended December 31, 2025 was $856 thousand, primarily from the nutraceutical business, down 35% from prior year due to operational difficulties affecting Amazon sales [S1].
• The company has an accumulated deficit of approximately $87 million as of December 31, 2025 [S1].
• Operating loss increased to $8.374 million for the year ended December 31, 2025, driven by higher general and administrative expenses [S1].
• Research and development expenses increased to $2.097 million in 2025, reflecting increased regulatory and patent-related costs [S1].
• The company has not generated significant revenue from pharmaceutical product sales to date [S1].
• SciSparc's SCI-110 drug candidate is based on a combination of THC and a proprietary PEA formulation, aiming to induce a 'sparing effect' for CNS diseases [S1].
• SCI-110 Phase IIa study at Yale showed a 21% average reduction in tic symptoms in TS patients, with good tolerability [S1].
• The company is pursuing FDA orphan drug designation for SCI-110 in TS but has not yet obtained it [S1].
• SciSparc's pharmaceutical development faces competition from other cannabinoid-based therapies and pharmaceutical companies with greater resources [S1].
• Pricing and reimbursement challenges exist in the US and foreign markets, with government and third-party payors increasingly scrutinizing drug prices [S1].
• The company has experienced share price volatility related to clinical and acquisition news [N6][N4].